Researchers at UC San Francisco have developed a groundbreaking approach to treating Parkinson’s disease with a new type of brain implant called...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - NEWS.MEDICAL.NET - A la Une - 23/Aug 08:31
Risankizumab outperforms ustekinumab in treating moderate-to-severe Crohn’s disease
Researchers compare the therapeutic efficacy of risakizumab and ustekinumab for the treatment of moderate-to-severe Crohn’s disease.
Articles similaires
Smart brain pacemakers could revolutionize Parkinson’s disease treatment
knowridge.com - 03/Sep 15:04
Researchers at UC San Francisco have developed a groundbreaking approach to treating Parkinson’s disease with a new type of brain implant called...
Scientists find new treatment that could combat Alzheimer’s disease
knowridge.com - 08/Sep 10:30
A team of researchers in Japan has discovered a potential new way to treat Alzheimer’s disease using dopamine, a chemical naturally produced in the...
Scientists find new treatment that could combat Alzheimer’s disease
knowridge.com - 08/Sep 10:30
A team of researchers in Japan has discovered a potential new way to treat Alzheimer’s disease using dopamine, a chemical naturally produced in the...
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
qatarnewswire.qa - 03/Sep 12:17
REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance...
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
qatarnewswire.qa - 03/Sep 12:17
REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance...
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
menafocus.qa - 03/Sep 12:17
REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance...
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
pressarabia.qa - 03/Sep 12:17
REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance...
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
pressarabia.qa - 03/Sep 12:17
REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance...
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
emiratesnewswire.ae - 03/Sep 12:17
REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance...
Les derniers communiqués
-
Aucun élément